A Phase I Study of MLN6907 in Patients With Metastatic Colorectal

NCT02056015 ↗

Phase 1 Completed 20 enrolled Millennium Pharmaceuticals, Inc.

NaSingle-groupOpen-labelDiagnostic

Summary

This study is a first-in-human (FIH), single-dose, open-label, phase 1 study designed to assess the safety, pharmacokinetics (PK), distribution, and radiation dosimetry of \[68Ga\]MLN6907 after a single intravenous (IV) administration. Patients with Metastatic Colorectal Carcinoma who are scheduled for resection of liver metastases as part of their treatment plan will be eligible for enrollment.

Timeline

Start: 2015-06
Primary completion: 2015-09
Completion: 2015-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[68Ga]MLN6907	Unknown	—	Intravenous

Indications

No indication recorded.